MSD

News

Owkin and MSD join forces on AI-powered digital pathology

Pharma group MSD has joined forces with Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for

News

MSD claims 2nd FDA approval for Welireg, in kidney cancer

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f

News

MSD, Moderna cancer vaccine aces melanoma study

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma.

News

MSD, Moderna take mRNA jab into phase 3 for lung cancer

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non

News

BMS chases MSD/Seagen with first-line bladder cancer filing

The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting

News

FDA starts review of Padcev/Keytruda for bladder cancer

The FDA has kicked off a priority review of a new combination regimen for previously untreated, locally advanced or metastatic urothelial carcinoma (UC), the most common f

Owkin and MSD join forces on AI-powered digital pathology

MSD claims 2nd FDA approval for Welireg, in kidney cancer

MSD, Moderna cancer vaccine aces melanoma study

MSD, Moderna take mRNA jab into phase 3 for lung cancer

BMS chases MSD/Seagen with first-line bladder cancer filing

FDA starts review of Padcev/Keytruda for bladder cancer

Alzheimer's biotech Korsana to go public via reverse merger

Using AI-driven synthetic personas to take your insights fur...

MSD

Editor's Picks